ST 1535
Alternative Names: ST1535Latest Information Update: 16 Jul 2016
At a glance
- Originator sigma-tau SpA
- Class Antiparkinsonians; Purines; Triazoles
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in Italy (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease in Italy (PO)
- 30 Jul 2009 Phase-I clinical trials in Neurodegenerative disorders in Italy (PO)